Department of Anesthesiology, Columbia University Vagelos College of Physicians and Surgeons, 622 West 168th St, PH5-505, New York, NY, 10032, USA.
Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.
Subst Abuse Treat Prev Policy. 2020 Feb 17;15(1):12. doi: 10.1186/s13011-020-00257-7.
State governments in the United States are increasingly viewing marijuana legalization as a policy option for controlling the opioid epidemic under the premise that marijuana is a less harmful substitute for opioids. The purpose of this study is to assess whether marijuana use is associated with decreased odds of prescription opioid use.
A cross-sectional study design was applied to toxicological testing data from two national samples of drivers: 1) the 2011-2016 Fatality Analysis Reporting System (FARS) and 2) the 2013-2014 National Roadside Survey of Alcohol and Drug Use by Drivers (NRS). Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) estimated from multivariable logistic regression models were used to assess the associations of marijuana use with prescription opioid use and alcohol use.
Among the 47,602 drivers from the FARS, 15.7% tested positive for marijuana and 6.9% positive for prescription opioids. Compared with drivers testing negative for marijuana, those testing positive for marijuana were 28% more likely to test positive for prescription opioids (adjusted OR = 1.28, 95% CI = 1.15-1.42). Among the 7881 drivers from the NRS, 7.9% tested positive for marijuana and 4.5% positive for prescription opioids. Relative to drivers testing negative for marijuana, those testing positive for marijuana were twice as likely to test positive for prescription opioids (adjusted OR = 2.03, 95% CI = 1.29-3.20). In both study samples, marijuana use was associated with significantly increased odds of alcohol positivity.
Drivers who test positive for marijuana are significantly more likely to test positive for prescription opioids. Longitudinal studies with rigorous designs and toxicological testing data are needed to further address the substitution hypothesis between marijuana and prescription opioids.
美国各州政府越来越多地将大麻合法化视为控制阿片类药物流行的政策选择,前提是大麻是阿片类药物的一种危害较小的替代品。本研究旨在评估大麻使用是否与减少处方类阿片类药物使用的几率有关。
本研究采用了横断面研究设计,对来自两个全国性驾驶员毒理学检测样本的数据进行了分析:1)2011-2016 年的致命性事故分析报告系统(FARS);2)2013-2014 年全国酒精和毒品使用路边调查(NRS)。使用多变量逻辑回归模型估计调整后的比值比(OR)和 95%置信区间(CI),以评估大麻使用与处方类阿片类药物使用和酒精使用之间的关联。
在 FARS 中,47602 名驾驶员中有 15.7%检测出大麻呈阳性,6.9%检测出处方类阿片类药物呈阳性。与未检测出大麻的驾驶员相比,检测出大麻呈阳性的驾驶员检测出处方类阿片类药物呈阳性的可能性高出 28%(调整后的 OR=1.28,95%CI=1.15-1.42)。在 NRS 中,7881 名驾驶员中有 7.9%检测出大麻呈阳性,4.5%检测出处方类阿片类药物呈阳性。与未检测出大麻的驾驶员相比,检测出大麻呈阳性的驾驶员检测出处方类阿片类药物呈阳性的可能性是其两倍(调整后的 OR=2.03,95%CI=1.29-3.20)。在两个研究样本中,大麻的使用均与酒精呈阳性的几率显著增加相关。
检测出大麻呈阳性的驾驶员检测出处方类阿片类药物呈阳性的可能性显著更高。需要进行设计严谨的纵向研究和毒理学检测数据,以进一步解决大麻和处方类阿片类药物之间的替代假说。